Italia - italiano - Ministero della Salute

ceva salute animale s.p.a. - toltrazuril - toltrazuril - 50 mg/ml - toltrazuril

Unione Europea - italiano - EMA (European Medicines Agency)

advanz pharma limited - obeticholic acido - cirrosi epatica, biliare - bile e terapia del fegato - ocaliva è indicato per il trattamento della colangite biliare (noto anche come la cirrosi biliare primaria) in combinazione con acido ursodesossicolico (udca) negli adulti con risposta inadeguata al udca o come monoterapia negli adulti incapaci di tollerare udca.

Unione Europea - italiano - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran di sodio - amiloidosi familiare - altri farmaci sul sistema nervoso - onpattro è indicato per il trattamento di ereditario transtiretina-mediata amiloidosi (hattr amiloidosi) in pazienti adulti con la fase 1 o la fase 2 polineuropatia.

Unione Europea - italiano - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, cellule squamose - agenti antineoplastici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Italia - italiano - Ministero della Salute

vetpharma animal health, s.l. - deltametrina - deltametrina - 4 g - deltamethrin

Italia - italiano - Ministero della Salute

vetpharma animal health, s.l. - deltametrina - deltametrina - 4 g - deltamethrin

Unione Europea - italiano - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porfiria, insufficienza epatica - varie apparato digerente e metabolismo prodotti - trattamento acuto di porfiria epatica (ahp) negli adulti e negli adolescenti di età compresa tra 12 anni e più vecchi.

Unione Europea - italiano - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - altro apparato digerente e metabolismo prodotti, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Italia - italiano - Ministero della Salute

zoetis belgium sa - bedinvetmab - bedinvetmab - 5 mg, bedinvetmab - 10 mg, bedinvetmab - 30 mg, bedinvetmab - 15 mg, bedinvetmab - 20 mg - bedinvetmab

Unione Europea - italiano - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - agenti antineoplastici - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.